Celiac Disease Prevention
Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły
Zaloguj się Zarejestruj się
Link zostanie zapisany w schowku
Status
Sponsorzy
Kuopio University Hospital
Współpracownicy
University of Eastern Finland
University of Turku
Finnish Institute for Health and Welfare
Päivikki and Sakari Sohlberg Foundation, Finland
Kätilöopisto Maternity Hospital
BADANIE KLINICZNE: NCT00617838
BioSeek: nct00617838
Słowa kluczowe
Abstrakcyjny
Celiac disease is an autoimmune disease induced by wheat gluten. Destruction of epithelial cells and microvilli on gut mucosa is causing a "flat mucosa" and an absorption defect. The diagnosis is based on typical microscopical finding in biopsy specimens but serum antibodies to tissue transglutaminase and certain gliadin peptides are strongly associated with the pathology. Severe diarrhoea associated with growth disturbance in infancy was historically characterising the disease but is nowadays rare. Clinically more mild forms including silent disease are very common. Studies based on antibody screening and biopsies done in autoantibody positive subjects have confirmed a frequency of about 1-2% in adult population. Undiagnosed disease is associated with deficiencies of nutrients and vitamins leading to various chronic symptoms like anaemia, osteoporosis and general fatigue. It has also been recently found that undiagnosed celiac disease may be associated with general underachievement in society probably associated with common psychological symptoms like fatigue and depression during the adolescence. The disease is treated by complete elimination of wheat, rye and barley in the diet, which is laborious and causing considerable extra costs in nutrition.
Much progress has been recently made in understanding of the genetic background and immune markers associated with the disease as well as in understanding those patterns of gluten introduction in infancy, which might be connected to a high disease risk. Our aim in this study is in the first phase to identify children at high genetic risk (around 10%) and in a follow-up study to define:
1. Are the age, dose of gluten and presence of simultaneous breast feeding at the introduction of gluten associated with the risk of celiac disease?
2. Is it possible to decrease the frequency of celiac disease by nutritional counselling?
3. Is it possible to predict development of celiac disease by immunological tests before the development of mucosal lesion
If we can confirm, that optimising the conditions at the introduction of wheat gluten in infancy diet significantly reduces the disease incidence, will this have an important effect on the nutritional recommendations concerning the diet in infancy. Combining genetic screening and immunological tests might also offer a way to reduce the frequency of celiac disease and help in early diagnosis and organisation of an adequate treatment
Daktyle
Ostatnia weryfikacja: | 07/31/2013 |
Pierwsze przesłane: | 02/05/2008 |
Szacowana liczba przesłanych rejestracji: | 02/14/2008 |
Wysłany pierwszy: | 02/17/2008 |
Ostatnia aktualizacja przesłana: | 08/21/2013 |
Ostatnia opublikowana aktualizacja: | 08/22/2013 |
Rzeczywista data rozpoczęcia badania: | 09/30/2007 |
Szacowana data zakończenia podstawowej działalności: | 07/31/2014 |
Szacowana data zakończenia badania: | 11/30/2014 |
Stan lub choroba
Celiac Disease
Interwencja / leczenie
Other: 1
Faza
-
Grupy ramion
Ramię | Interwencja / leczenie |
---|---|
Active Comparator: 1 Optimization of gluten introduction by nutritional councelling | Other: 1 Optimization of gluten introduction by nutritional counselling |
No Intervention: 2 No specific nutritional councelling. Follow-up of gluten introduction |
Kryteria kwalifikacji
Płeć kwalifikująca się do nauki | All |
Przyjmuje zdrowych wolontariuszy | tak |
Kryteria | Inclusion Criteria: - Presence of HLA-risk alleles DQA1*05 and DQB1*02 Exclusion Criteria: - Lack of these HLA risk alleles |
Wynik
Podstawowe miary wyników
1. development of transglutaminase antibodies [2-4 year age]
Miary wyników wtórnych
1. gliadin peptide antibodies [2-4 years]
2. mucosal biopsy in TGA positive childre [2-4 years]